Capital, Llc Armistice Capi... Net Worth

The estimated Net Worth of Capital, Llc Armistice Capi... is at least $419 millió dollars as of 16 August 2021. Capital Capi owns over 50,000 units of Vaxart Inc stock worth over $36,942,000 and over the last 7 years Capital sold VXRT stock worth over $381,883,541.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Capi VXRT stock SEC Form 4 insiders trading

Capital has made over 154 trades of the Vaxart Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital bought 50,000 units of VXRT stock worth $138,000 on 16 August 2021.

The largest trade Capital's ever made was selling 27,612,053 units of Vaxart Inc stock on 26 June 2020 worth over $267,008,553. On average, Capital trades about 802,505 units every 9 days since 2017. As of 16 August 2021 Capital still owns at least 39,300,000 units of Vaxart Inc stock.

You can see the complete history of Capital Capi stock trades at the bottom of the page.

Insiders trading at Vaxart Inc

Over the last 7 years, insiders at Vaxart Inc have traded over $322,706,538 worth of Vaxart Inc stock and bought 8,979,091 units worth $2,899,807 . The most active insiders traders include Capital, Llc Armistice Capi..., Steven Lo és Wouter Latour. On average, Vaxart Inc executives and independent directors trade stock every 57 days with the average trade being worth of $1,309,363. The most recent stock trade was executed by W. Mark Watson on 18 June 2024, trading 20,000 units of VXRT stock currently worth $13,600.

What does Vaxart Inc do?

since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.

Complete history of Capital Capi stock trades at Alimera Sciences, AMAG Pharmaceuticals, Bio-Path Inc, Cerecor Inc, AB Active ETFs Inc, Onconova Therapeutics Inc, Tenax Therapeutics Inc, Tetraphase Pharmaceuticals, Achieve Life Sciences, Aytu BioPharma Inc és Vaxart Inc

Vaxart Inc executives and stock owners

Vaxart Inc executives and other stock owners filed with the SEC include:

• Wouter Latour,
  Chairman of the Board
• Cezar Andrei Floroiu M.B.A.,
  CEO, Pres, Principal Financial Officer & Director
• Dr. Sean N. Tucker,
  Sr. VP & Chief Scientific Officer
• Margaret A. Echerd,
  Sr. VP & Principal Accounting Officer
• Sean Tucker,
  Chief Scientific Officer
• Margaret Echerd,
  Principal Accounting Officer, Vice President, Controller
• Anne VanLent,
  Independent Director
• Michael Finney,
  Independent Director
• Robert Yedid,
  Lead Independent Director
• Todd Davis,
  Independent Director
• Karen Wilson,
  Independent Director
• Keith Maher,
  Director
• Steven Boyd,
  Director
• Andrei Floroiu,
  Chief Executive Officer, Principal Financial Officer, Director
• Edward B. Berg,
  Sr. VP & Gen. Counsel
• John M. Harland M.B.A., CPA,
  Consultant
• Dr. James F. Cummings M.D.,
  Chief Medical Officer
• Dr. Rajesh Kapoor Ph.D.,
  Sr. VP of Quality
• Dr. Richard M. Schwartz,
  Sr. VP of Technical Operations
• Brant Biehn,
  Sr. VP of Bus. Operations
• Shaily Jaini Garg,
  Sr. VP of Clinical Devel. & Project Management
• Julie M Cherrington,
  Director
• Edward B Berg,
  SVP, General Counsel
• John M Harland,
  Chief Financial Officer
• Richard J Markham,
  Director
• Geoffrey F Cox,
  Director
• John P Richard,
  Director
• Phillip E Lee,
  Chief Financial Officer
• David E. Wheadon,
  Director
• James F. Cummings,
  Chief Medical Officer
• W. Mark Watson,
  Director
• Elaine J Heron,
  Director
• Steven Lo,
  President, Chief Exec Officer
• Fuad Ahmad,
  Interim CFO